Report
EUR 13.70 For Business Accounts Only

NICHI-IKO PHARMA sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of NICHI-IKO PHARMA (JP), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 18, 2022, the closing price was JPY 858.00 and its potential was estimated at JPY 900.90.
Underlying
Nichi-Iko Pharmaceutical Co. Ltd.

Nichi-Iko Pharmaceutical is mainly engaged in the manufacture, sale, distribution, import and export of pharmaceutical products, quasi drugs and other medical products. Co. provides its products to medical institutions, such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. Co.'s principal products include drugs used for the treatment of circulatory, digestive, respiratory, as well as central and peripheral nervous systems.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch